As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase ...

Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American ...

Multiple system atrophy (MSA) is a progressive disorder of the nervous system. The neurodegenerative disease is characterized by symptoms that affect movement and the autonomic nervous system.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...

Health officials in Hood River County, Oregon, are investigating three cases of a rare and fatal brain disease known as ...

Tommy Tiernan Show recap: Cork jockey Davy Russell pays tribute to 'beautiful chap' Michael O’Sullivan ...

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease< ...

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of ...

See α-Synuclein. Candidate tracer SY08 detects α-synuclein deposits in the brainstem (right) and parietal cortex (left) of ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and then, ...